Reports

Overview of Original Subscription Model and Features of LA and WA Proposals

An overview of the original subscription-based Netflix model proposed and the proposals put forth by Louisiana and Washington.

Authors

Originally published on 01/29/2019

The Drug Pricing Lab has proposed a subscription-based payment model that offers an unlimited amount of medications over a predetermined period of time specified in a multi-year contract with a state coalition of payers paying a flat annual subscription fee.

On January 10, 2019, officials in the state of Louisiana announced plans to proceed with a subscription-based payment model for providing hepatitis C treatment and have published a solicitation for offers to manufacturers to enter into negotiations. Additionally, Washington state released a request for proposals for a “modified subscription model” for treating HCV on January 22.

Here we present an overview of the original subscription-based Netflix model proposed and the proposals put forth by Louisiana and Washington.

Share

Authors

Research & Insights

We conduct non-partisan, independent research, and make our work accessible and informative to policymakers and the general audience alike. Browse our featured research or explore our work by article type.

The "Netflix Model" of Financing Hepatitis C Treatment
An alternative payment model is proposed to support a population-level payment paradigm.
JAMA Viewpoint 11/20/2018
The Conflict Between QALYs and Well-Funded Patient Advocacy Groups
The goal of a QALY is to figure out how much any given drug is worth to a society so that we, as a society, have a benchmark to evaluate the price of pharmaceutical products.
Relentless Health Value 12/10/2020
Remdesivir Less Expensive for "Government Programs"? Not So Fast.
Two options are proposed if Gilead wishes to offer the discounts to the full array of government programs.
Drug Pricing Lab 07/01/2020
Blueprints for Indication-Specific Pricing
Several approaches that rewire existing reimbursement conventions as alternatives to facilitate ISP are proposed.
Drug Pricing Lab 05/19/2020
Pharmaceutical Products and Their Value
Steep increases in prices and spending on prescription drugs in the United States have triggered public outrage and questions about their value.
Value in Health 03/29/2020
Drop in Cancer Deaths Reflect Failures of Our Society. Really.
Despite declining cancer death rates, the nation still presents societal failures to improve the state of our population's health.
The Boston Globe 02/21/2020
Dissecting PhRMA's Opposition to H.R. 3 Lower Drug Costs Now…
Dr. Peter Bach responds to PhRMA's stance of opposition to H.R. 3 Lower Drug Costs Now Act of 2019.
STAT News 10/11/2019
Time to Throw in the Towel on Biosimilars
Peter Bach and Mark Trusheim of MIT Sloan School of Management underscore the drawbacks of Washington's preferred solution to introduce competition for biologics, the biosimilar model.
The Wall Street Journal 08/21/2019
Mortgaging New Treatments Kicks the Can on High Drug Prices
The launch price for one-time gene therapy Zolgensma presents various implications.
Morning Consult 07/09/2019
A $475,000 price tag for a new cancer drug: crazy…
Drug Pricing Lab op-ed in STAT News discusses indication-specific pricing of Kymriah.
STAT News 08/31/2017
US Drug Prices And R&D, Take 2: A Reply To…
To answer Health Affairs responses, Peter Bach and Nancy Yu point back to the research, emphasizing the original intent of the conservative R&D cost assumptions.
Health Affairs Blog 07/27/2017
Prevalence of Off-Label Use and Spending Among Patent-Protected Chemotherapies
The prevalence of off-label anticancer drug use is not well characterized.
JCO 02/19/2013

Featured News

See All News
The Washington Post 07/12/2017

High Prices Continue to Limit Access to Hepatitis C Treatment

The Washington Post takes a deeper dive on the issues highlighted in the Drug Pricing Lab's budget allocator tool.
Read Article
Newsletter

Stay up to date on our work and news